Cancer Prevention Pharmaceuticals in Collaboration with the NCI and Vanderbilt University Medical Center Initiates Phase 2 Trial to Evaluate CPP-1X in Patients with High Risk of Gastric Cancer

Cancer Prevention Pharmaceuticals has launched a Phase 2 Clinical trial to evaluate the drug CPP-1x in patients with precancerous gastric lesions who are at high risk for gastric cancer. Funded by NCI, the study has a goal of enrolling 300 patients in an attempt to determine if the drug can prevent gastric cancer.